Investigating Intestinal Permeability of Bortezomib Using a Validated HPLC-UV Method.
Sign Up to like & getrecommendations! Published in 2019 at "Drug research"
DOI: 10.1055/s-0043-115648
Abstract: Bortezomib (BTZ), as a proteasome inhibitor, has been used for treatment of patients with relapsed/refractory multiple myeloma and mantle cell lymphoma. BTZ is available for intravenous injection or subcutaneous administration. In this study, for evaluating… read more here.
Keywords: intestinal permeability; using validated; permeability; validated hplc ... See more keywords